Piramal Pharma has seen a substantial rise in its stock performance this year, with its share price jumping by 23% in September alone and a significant 68% year-to-date (YTD). This growth has been attributed to strong trading volumes and the company's promising growth prospects, which have driven investor interest.
The surge in share price has made Piramal Pharma a focus for investors, many of whom are looking to buy shares online and capitalise on this growth.
September surge: 23% increase in stock value
Piramal Pharma's share price increased 23% during the first few weeks of September 2024. This rise can be attributed to robust investor confidence in the company's future growth, bolstered by strong trading volumes in the pharmaceutical sector.
Despite the sharp rise in the stock price, analysts have observed a minor correction during a Thursday trading session in September, which was driven by profit booking. This indicates that some investors took advantage of the stock's strong performance to sell shares at a profit. However, the correction was minor and did not significantly impact the overall positive trend.
Year-to-date performance: 68% growth
Piramal Pharma has seen an impressive 68% growth in its share price YTD. This performance reflects the company's strategic focus on expanding its operations and increasing its capabilities in high-growth areas such as drug manufacturing, healthcare solutions, and critical care products. The pharmaceutical giant has benefitted from global healthcare trends, and its strategic moves have strengthened investor confidence, leading to an increase in buy shares online activity.
Positive impact of the US Biosecure Act
The recent US House of Representatives passage of the Biosecure Act has boosted investor sentiment towards Indian pharmaceutical companies, including Piramal Pharma. The Act is designed to blacklist Chinese biotech companies, and this shift in US policy is expected to benefit Indian companies that specialise in small molecule manufacturing. This includes Piramal Pharma, which has advanced its capabilities in the antibody-drug conjugate space. As US pharmaceutical firms look to relocate their manufacturing operations away from China, Piramal Pharma stands to gain from an inflow of new orders.
As a result, Indian firms like Piramal Pharma are expected to see an increase in business opportunities, leading more investors to consider the stock a favourable option when they look to buy shares online.
Piramal Pharma's Q1 results
Piramal Pharma's strong stock performance can also be linked to its Q1 results for the financial year 2024-2025. The company reported a narrowed consolidated net loss of ₹88.64 crore for the first quarter ended June 30, 2024. This represents an improvement over the previous fiscal year, where the company reported a net loss of ₹98.58 crore in the same quarter.
The company's consolidated income from operations for the quarter stood at ₹1,951.14 crore, up from ₹1,748.85 crore in the same period last year. Nandini Piramal, the chairperson of Piramal Pharma, highlighted the company's CDMO division as a key driver of this growth, with steady order inflows for on-patent commercial manufacturing.
Final words
The recent surge in Piramal Pharma's stock price has made it an attractive option for investors looking to buy shares online. With strong trading volumes, robust financial performance, and positive market trends, the company is well-positioned for future growth. The passage of the US Biosecure Act is expected to provide further opportunities for Piramal Pharma, particularly in the CDMO space, as US firms seek alternatives to Chinese manufacturers.
Analysts have suggested that investors should consider a "buy on dip" approach, taking advantage of any short-term price corrections to purchase shares at a more favourable price. This strategy allows investors to enter the market at lower price points while still benefiting from the overall positive trend in Piramal Pharma's stock performance. Investors looking to buy shares online may find this stock a compelling option, with analysts maintaining a positive long-term outlook for the company.
For android only